These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 2572713)
21. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D Front Immunol; 2018; 9():977. PubMed ID: 29780393 [TBL] [Abstract][Full Text] [Related]
22. Antileukemia activity of a natural killer cell line against human leukemias. Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753 [TBL] [Abstract][Full Text] [Related]
23. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor. Chang WC; Hsiao MH; Pattengale PK Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400 [TBL] [Abstract][Full Text] [Related]
24. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Coles SJ; Wang EC; Man S; Hills RK; Burnett AK; Tonks A; Darley RL Leukemia; 2011 May; 25(5):792-9. PubMed ID: 21274000 [TBL] [Abstract][Full Text] [Related]
25. A VEGFR-3 antagonist increases IFN-γ expression on low functioning NK cells in acute myeloid leukemia. Lee JY; Park S; Kim DC; Yoon JH; Shin SH; Min WS; Kim HJ J Clin Immunol; 2013 May; 33(4):826-37. PubMed ID: 23404187 [TBL] [Abstract][Full Text] [Related]
26. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia. Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298 [TBL] [Abstract][Full Text] [Related]
27. Allospecific recognition of hemic cells in vitro by natural killer cells from athymic rats: evidence that allodeterminants coded for by single major histocompatibility complex haplotypes are recognized. Vaage JT; Dissen E; Ager A; Fossum S; Rolstad B Eur J Immunol; 1991 Sep; 21(9):2167-75. PubMed ID: 1716212 [TBL] [Abstract][Full Text] [Related]
28. Natural killer-interferon system in patients with preleukaemic states. Takagi S; Kitagawa S; Takeda A; Minato N; Takaku F; Miura Y Br J Haematol; 1984 Sep; 58(1):71-81. PubMed ID: 6466573 [TBL] [Abstract][Full Text] [Related]
30. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes. Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320 [TBL] [Abstract][Full Text] [Related]
31. Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia. Dai YJ; He SY; Hu F; Li XP; Zhang JM; Chen SL; Zhang WN; Sun HM; Wang DW Mol Cancer; 2021 Jan; 20(1):8. PubMed ID: 33402171 [TBL] [Abstract][Full Text] [Related]
32. beta-Endorphin augments the cytolytic activity and interferon production of natural killer cells. Mandler RN; Biddison WE; Mandler R; Serrate SA J Immunol; 1986 Feb; 136(3):934-9. PubMed ID: 2934481 [TBL] [Abstract][Full Text] [Related]
33. A large subpopulation of lymphocytes with T helper phenotype (Leu-3/T4+) exhibits the property of binding to NK cell targets and granular lymphocyte morphology. Velardi A; Grossi CE; Cooper MD J Immunol; 1985 Jan; 134(1):58-64. PubMed ID: 3155472 [TBL] [Abstract][Full Text] [Related]
34. Targeting CD157 in AML using a novel, Fc-engineered antibody construct. Krupka C; Lichtenegger FS; Köhnke T; Bögeholz J; Bücklein V; Roiss M; Altmann T; Do TU; Dusek R; Wilson K; Bisht A; Terrett J; Aud D; Pombo-Villar E; Rohlff C; Hiddemann W; Subklewe M Oncotarget; 2017 May; 8(22):35707-35717. PubMed ID: 28415689 [TBL] [Abstract][Full Text] [Related]
36. Natural killer cell activity in the rat. VI. Characterization of rat large granular lymphocytes as effector cells in natural killer and antibody-dependent cellular cytotoxic activities. Fukui H; Overton WR; Herberman RB; Reynolds CW J Leukoc Biol; 1987 Feb; 41(2):130-42. PubMed ID: 2433376 [TBL] [Abstract][Full Text] [Related]
37. NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions. Wang Y; Chen C; Dong F; Ma S; Xu J; Gong Y; Cheng H; Zhou Y; Cheng T; Hao S Sci China Life Sci; 2015 Dec; 58(12):1288-98. PubMed ID: 26588911 [TBL] [Abstract][Full Text] [Related]
38. Decreased natural killer cell activity versus normal natural killer cell markers in mononuclear cells from patients with smouldering leukemia. Sørskaar D; Førre O; Albrechtsen D; Stavem P Scand J Haematol; 1986 Aug; 37(2):154-61. PubMed ID: 3764338 [TBL] [Abstract][Full Text] [Related]
40. NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2. Braciak TA; Wildenhain S; Roskopf CC; Schubert IA; Fey GH; Jacob U; Hopfner KP; Oduncu FS J Transl Med; 2013 Nov; 11():289. PubMed ID: 24237598 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]